EQL — EQL Pharma AB Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesHighly SpeculativeSmall CapNeutral

Annual income statement for EQL Pharma AB, fiscal year end - March 31st, SEK millions except per share, conversion factor applied.

	C2020 March 31st	R2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	SAS	SAS	SAS	SAS	SAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	72	179	410	260	264
Cost of Revenue
Gross Profit	72	51	95.7	116	115
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Other Operating Expenses
Total Operating Expenses	68.9	168	371	219	232
Operating Profit	3.16	11.5	38.8	41.3	32.6
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	2.72	10.4	36	39	28.6
Provision for Income Taxes
Net Income After Taxes	2.71	10.4	31.5	30.9	22.7
Net Income Before Extraordinary Items
Net Income	2.71	10.4	31.5	30.9	22.7
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	2.71	10.4	31.5	30.9	22.7
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.093	0.357	1.09	1.05	0.781
Dividends per Share